ERBB2 and breast carcinoma: High prevalence of breast carcinoma and the multifaceted spectrum of treatment modalities, coupled with the distinctive profile of trastuzumab as the inaugural HER-2 targeted therapy integrated into the therapeutic armamentarium for breast carcinoma management, encompassing both early-stage and metastatic scenarios, has steered the investigative spotlight onto this seminal agent (Maadi et al., 2021).